Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion

Experts give their concluding thoughts on cardiovascular care and closing disparity gaps to optimize patient outcomes.

EP: 1.Disparities in Cardiovascular Care for Diverse Populations

EP: 2.Innovation vs Access: Supporting Underserved Communities

EP: 3.Exploring Polypharmacy: Adherence, Communication, and Outcomes

EP: 4.Gender-Based Disparities in Cardiovascular Disease

EP: 5.Peripheral Arterial Disease Awareness for Minority Populations

EP: 6.Community Partnership: Increasing Public Awareness of CVD

EP: 7.Recent Data Reveals Disparities in Cardiovascular Care

EP: 8.Identifying Social Determinants of Health in Cardiovascular Care

EP: 9.Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease

EP: 10.Developing Practical Solutions to Improve Cardiovascular Care

EP: 11.Advancing Cardiovascular Care Through Technological Innovation

EP: 12.Desired Technology Innovations to Prevent Cardiovascular Disease

EP: 13.Measuring Implicit Bias

EP: 14.Achieving Equitable Representation in Clinical Studies

Now Viewing

EP: 15.Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion

Related Videos

Related Content

Advertisement

July 14th 2025

Medicare Inflation Rebates Show Limited Impact on Drug Price Trends

Brooke McCormick

Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 14th 2025

HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC

Julia Bonavitacola

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 14th 2025

Concerns Persist Over Reliance on Surrogate End Points in FDA Accelerated Approvals

Brooke McCormick

Many FDA accelerated approvals continue to rely heavily on surrogate endpoints, raising ongoing uncertainty about the true clinical benefits of these therapies.

July 13th 2025

Updated OVARIO Trial Results Reinforce Niraparib Plus Bevacizumab Maintenance for Advanced Ovarian Cancer

Brooke McCormick

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

Related Content

Advertisement

July 14th 2025

Medicare Inflation Rebates Show Limited Impact on Drug Price Trends

Brooke McCormick

Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 14th 2025

HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC

Julia Bonavitacola

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 14th 2025

Concerns Persist Over Reliance on Surrogate End Points in FDA Accelerated Approvals

Brooke McCormick

Many FDA accelerated approvals continue to rely heavily on surrogate endpoints, raising ongoing uncertainty about the true clinical benefits of these therapies.

July 13th 2025

Updated OVARIO Trial Results Reinforce Niraparib Plus Bevacizumab Maintenance for Advanced Ovarian Cancer

Brooke McCormick

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.